Development of ligand-targeted liposomes for cancer therapy

Разработка липосом с лигандным наведением для терапии рака
Daryl C. Drummond, Keelung Hong, Dmitri B. Kirpotin, Christoph Mamot, John W. Park, Christopher C. Benz, Charles O. Noble, James D. Marks, Mark E. Hayes
2004-08-01

anti-HER2 immunoliposomal doxorubicincancer therapyligand-targeted liposomesmicellar insertion technologytargeted liposomal therapeutics
The continued evolution of targeted liposomal therapeutics has resulted in new agents with remarkable antitumour efficacy and relatively mild toxicity profiles. A careful selection of the ligand is necessary to reduce immunogenicity, retain extended circulation lifetimes, target tumour-specific cell surface epitopes, and induce internalisation and subsequent release of the therapeutic substance from the liposome. Methods for assembling targeted liposomes, including a novel micellar insertion technology, for incorporation of targeting molecules that efficiently transforms a non-targeted liposomal therapeutic to a targeted one, greatly assist the translation of targeted liposome technology into the clinic. Targeting strategies with liposomes directed at solid tumours and vascular targets are discussed. The authors believe the development of ligand-targeted liposomes is now in the advanced stage and offers unique and important advantages among other targeted therapies. Anti-HER2 immunoliposomal doxorubicin is awaiting Phase I clinical trials, the results of which should provide new insights into the promise of ligand-targeted liposomal therapies.
1
A novel micellar insertion technology enables efficient incorporation of targeting molecules, converting established nontargeted liposomal therapeutics into targeted formulations.
2
Anti-HER2 immunoliposomal doxorubicin was awaiting Phase I clinical trials to evaluate the clinical promise of ligand-targeted liposomal therapy.
3
Ligand selection is critical for targeted liposomes to minimize immunogenicity, preserve prolonged circulation, recognize tumor-specific epitopes, and promote internalization and drug release.
4
Targeted liposome strategies have been developed for both solid tumors and tumor-associated vascular targets.
5
The abstract characterizes ligand-targeted liposomes as an advanced therapeutic approach with potentially important advantages over other targeted therapies.

ligand-targeted liposomes for cancer therapy

their targeting strategies, ligand selection, tumor-cell internalization, therapeutic-substance release, and antitumor efficacy and toxicity

Publication Details
Publication Date
2004-08-01
Journal
Publisher
ISSN
Cited by
158
Access Type
Author Information
Authors
Daryl C. Drummond
Keelung Hong
Dmitri B. Kirpotin
Christoph Mamot
John W. Park
Christopher C. Benz
Charles O. Noble
James D. Marks
Mark E. Hayes
Explore further
Open the scid.ai AI chat with a ready-made request: it will find papers on a similar topic and help build a literature review.
Find similar papers in the chat →
Make a presentation
100%